By Adriano Marchese
Protara Therapeutics' stock jumped in premarket trading Thursday after reporting positive early results from its bladder cancer treatment trials.
Shares traded 69% higher ahead of the morning bell at $5.92.
The clinical-stage company said that patients in the intravesical trial studying its investigational cell-based therapy TARA-002 to treat non-muscle invasive bladder cancer have shown high complete response rates for up to six months, and as high as nine months for some patients.
The dataset includes 20 patients who were evaluable at three months, 18 patients who were evaluable at six months and three patients who were evaluable at nine months.
The trials are still ongoing, but Chief Executive Jesse Shefferman said that these are encouraging results which should be positive as it expands the breadth of the trials.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 05, 2024 08:44 ET (13:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.